迪哲医药：部分高管合计减持147.2万股，减持计划实施完毕

Core Viewpoint - Dize Pharmaceutical announced a share reduction plan by senior management due to personal financial needs related to tax payments for equity incentives, with specific share amounts and percentages outlined for each individual involved [1][2]. Group 1: Share Reduction Details - Yang Zhenfan plans to reduce up to 1,154,000 shares, accounting for 0.2512% of the total share capital [1]. - Chen Suqin intends to reduce up to 129,000 shares, representing 0.0281% of the total share capital [1]. - Qingbei Zeng and Honchung Tsui each plan to reduce up to 85,000 shares, each accounting for 0.0185% of the total share capital [1]. - Lv Hongbin plans to reduce up to 19,000 shares, which is 0.0041% of the total share capital [1]. - The reduction period is from July 18, 2025, to October 17, 2025, with prices determined by market conditions during this period [1]. Group 2: Implementation Results - As of July 23, 2025, the share reduction has been completed, with the following results: Yang Zhenfan reduced 1,154,000 shares (0.2512%), Chen Suqin reduced 129,000 shares (0.0281%), Qingbei Zeng reduced 85,000 shares (0.0185%), Honchung Tsui reduced 85,000 shares (0.0185%), and Lv Hongbin reduced 19,000 shares (0.0041%) [2]. - Dize Pharmaceutical's revenue composition for 2024 is entirely from the pharmaceutical manufacturing sector, accounting for 100.0% [2]. Group 3: Market Capitalization - As of the latest report, Dize Pharmaceutical has a market capitalization of 32.2 billion yuan [3].